Lu J - Search Results

1

Reprogramming of TAMs via the STAT3/CD47-SIRPα axis promotes acquired resistance to EGFR-TKIs in lung cancer.

Lu J, Li J, Lin Z, Li H, Lou L, Ding W, Ouyang S, Wu Y, Wen Y, Chen X, Yue P, Wang Y, Liu P, Lu J, Zhang J, Feng W, Zhang X. Lu J, et al. Cancer Lett. 2023 Jun 28;564:216205. doi: 10.1016/j.canlet.2023.216205. Epub 2023 May 4. Cancer Lett. 2023. PMID: 37146936

2

Identification of a novel autophagic inhibitor cepharanthine to enhance the anti-cancer property of dacomitinib in non-small cell lung cancer.

Tang ZH, Cao WX, Guo X, Dai XY, Lu JH, Chen X, Zhu H, Lu JJ. Tang ZH, et al. Cancer Lett. 2018 Jan 1;412:1-9. doi: 10.1016/j.canlet.2017.10.001. Epub 2017 Oct 9. Cancer Lett. 2018. PMID: 29024815

3

Osimertinib resistance in non-small cell lung cancer: Mechanisms and therapeutic strategies.

Tang ZH, Lu JJ. Tang ZH, et al. Cancer Lett. 2018 Apr 28;420:242-246. doi: 10.1016/j.canlet.2018.02.004. Epub 2018 Feb 7. Cancer Lett. 2018. PMID: 29425688 Review.

4

Metabolic Reprogramming Driven by IGF2BP3 Promotes Acquired Resistance to EGFR Inhibitors in Non-Small Cell Lung Cancer.

Lin Z, Li J, Zhang J, Feng W, Lu J, Ma X, Ding W, Ouyang S, Lu J, Yue P, Wan G, Liu P, Zhang X. Lin Z, et al. Among authors: lu j. Cancer Res. 2023 Jul 5;83(13):2187-2207. doi: 10.1158/0008-5472.CAN-22-3059. Cancer Res. 2023. PMID: 37061993

5

Paraptosis: a non-classical paradigm of cell death for cancer therapy.

Xu CC, Lin YF, Huang MY, Zhang XL, Wang P, Huang MQ, Lu JJ. Xu CC, et al. Acta Pharmacol Sin. 2024 Feb;45(2):223-237. doi: 10.1038/s41401-023-01159-7. Epub 2023 Sep 15. Acta Pharmacol Sin. 2024. PMID: 37715003 Review.

6

Ginsenoside Rh2 augmented anti-PD-L1 immunotherapy by reinvigorating CD8⁺ T cells via increasing intratumoral CXCL10.

Huang MY, Chen YC, Lyu WY, He XY, Ye ZH, Huang CY, He XL, Chen X, Chen X, Zhang B, Kai G, Zhang X, Li T, Huang M, Lu JJ. Huang MY, et al. Pharmacol Res. 2023 Dec;198:106988. doi: 10.1016/j.phrs.2023.106988. Epub 2023 Nov 19. Pharmacol Res. 2023. PMID: 37984507 Free article.

7

Identification of Bulbocodin D and C as novel STAT3 inhibitors and their anticancer activities in lung cancer cells.

He X, Fu J, Lyu W, Huang M, Mo J, Cheng Y, Xu Y, Zheng L, Zhang X, Qi L, Zhang L, Zheng Y, Huang M, Ni L, Lu J. He X, et al. Among authors: lu j. Chin J Nat Med. 2023 Nov;21(11):842-851. doi: 10.1016/S1875-5364(23)60521-7. Chin J Nat Med. 2023. PMID: 38035939

8

Uncover the anticancer potential of lycorine.

Zhang YM, Li T, Xu CC, Qian JY, Guo H, Zhang X, Zhan ZJ, Lu JJ. Zhang YM, et al. Chin Med. 2024 Sep 8;19(1):121. doi: 10.1186/s13020-024-00989-9. Chin Med. 2024. PMID: 39245716 Free PMC article. Review.

9

Increased Expression of IRE1α Associates with the Resistant Mechanism of Osimertinib (AZD9291)-resistant non-small Cell Lung Cancer HCC827/OSIR Cells.

Tang ZH, Su MX, Guo X, Jiang XM, Jia L, Chen X, Lu JJ. Tang ZH, et al. Anticancer Agents Med Chem. 2018;18(4):550-555. doi: 10.2174/1871520617666170719155517. Anticancer Agents Med Chem. 2018. PMID: 28730963

10

Osimertinib (AZD9291) decreases programmed death ligand-1 in EGFR-mutated non-small cell lung cancer cells.

Jiang XM, Xu YL, Huang MY, Zhang LL, Su MX, Chen X, Lu JJ. Jiang XM, et al. Acta Pharmacol Sin. 2017 Nov;38(11):1512-1520. doi: 10.1038/aps.2017.123. Epub 2017 Sep 7. Acta Pharmacol Sin. 2017. PMID: 28880013 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

33,973 results

Search Page

Filters